BE6A LUNG-01

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Feb 23, 2024 → Oct 26, 2026

Cited window

Dec 17, 2025 → Oct 26, 2026

Retrieved

Oct 28, 2026

Title

A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)

Registry

NCT06012435

Study IDs

SGNB6A-002 · C5751002 (Alias Study Number) · 2023-503827-25-01 (CTIS (EU))

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

762 actual

Start

2024-02-21 actual

Primary completion

2026-05-18 actual

Primary endpoint

Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –1 matching source (1 X thread) could not be read and is not included.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –18 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition are not representative of all HCP discussion. Source totals and reposts must not be interpreted as counts of independent clinical opinions.
• –Twenty-two potentially relevant sources without a direct trial name were not reviewed. One additional thread was unavailable and three passages were not fully assessed; unnamed or differently transcribed discussions may also be missing.
• –No protocol or exact-trial results publication was available in the sources reviewed, and no exact sigvotatug vedotin label was identified. The report cannot independently resolve detailed eligibility, statistical methods or benefit-risk conclusions.
• –The podcast does not establish which named individual delivered each statement. Its views remain attributed to unidentified speakers.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –The December 2025 discussion and June/October 2026 posts concern different sources and settings. Their dates do not establish a readout or session date, a change of mind, or a direct disagreement between speakers.

How reports are built and checked: Methods.

Last checked for new commentary Oct 28, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "BE6A LUNG-01" (NCT06012435), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "be6a-lung-01-06012435". If you cannot make requests, read https://www.erudio.com/reports/be6a-lung-01-nct06012435.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06012435", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06012435 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/be6a-lung-01-nct06012435.json
curl https://www.erudio.com/reports/be6a-lung-01-nct06012435.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "be6a-lung-01-06012435" })